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Abstract
The role of the reactive oxygen species-producing NADPH oxidase family of enzymes in
the pathology of influenza A virus infection remains enigmatic. Previous reports implicated
NADPH oxidase 2 in influenza A virus-induced inflammation. In contrast, NADPH oxidase 1
(Nox1) was reported to decrease inflammation in mice within 7 days post-influenza A virus
infection. However, the effect of NADPH oxidase 1 on lethality and adaptive immunity after
influenza A virus challenge has not been explored. Here we report improved survival and
decreased morbidity in mice with catalytically inactive NADPH oxidase 1 (Nox1*/Y) com-
pared with controls after challenge with A/PR/8/34 influenza A virus. While changes in lung
inflammation were not obvious between Nox1*/Y and control mice, we observed alterations
in the T cell response to influenza A virus by day 15 post-infection, including increased inter-
leukin-7 receptor-expressing virus-specific CD8+ T cells in lungs and draining lymph nodes
of Nox1*/Y, and increased cytokine-producing T cells in lungs and spleen. Furthermore, a
greater percentage of conventional and interstitial dendritic cells from Nox1*/Y draining
lymph nodes expressed the co-stimulatory ligand CD40 within 6 days post-infection.
Results indicate that NADPH oxidase 1 modulates the innate and adaptive cellular immune
response to influenza virus infection, while also playing a role in host survival. Results sug-
gest that NADPH oxidase 1 inhibitors may be beneficial as adjunct therapeutics during
acute influenza infection.
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Introduction
Despite extensive influenza virus surveillance and seasonal influenza vaccination coverage,
influenza A virus (IAV) remains a major threat to public health. Seasonal influenza viruses
cause illness in 2–5 million individuals annually, and 250,000–500,000 will succumb to compli-
cations from the disease [1]. Furthermore, the continual reassortment of IAVs within wild
birds and domestic animals drives the occasional emergence of avian or swine influenza viruses
that can infect humans [2, 3]. Some of these prove to be highly pathogenic, such as H5N1 and
H7N9, which are fatal in 20–60% of individuals [4]. In the majority of lethal cases of influenza,
death is attributed to acute respiratory distress syndrome [5], a more severe form of acute lung
injury [6]. Current efforts to combat death related to IAV infection target the virus: vaccination
and antiviral therapy. Both of these approaches are vulnerable to loss of efficacy due to viral
mutations [7, 8]. Furthermore, several lines of investigation have implicated the host immune
system as a contributing factor to pathology [9–11]. Along with vaccination and antivirals,
there has been interest in development of adjunct therapeutics to decrease the inflammatory
processes that underlie acute lung injury/acute respiratory distress syndrome by targeting the
host immune system [12–14]. Such a strategy has been shown to improve outcomes of IAV
infection in mouse models [10, 15, 16] and in the clinic [17]. These results underscore the
potential of adjunct therapeutics to decrease the disease burden of IAV.
Reactive oxygen species (ROS) have been implicated in the lung pathology associated with
severe cases of seasonal or pandemic IAV [18–24]. Superoxide produced by NADPH oxidase 2
(Nox2) has been shown to contribute to influenza-mediated lung pathology [23, 25, 26]. How-
ever, other sources of ROS in the lung include the Nox1 and Nox4 isoenzymes, as well as the
closely related dual oxidase enzymes (Duox1 and Duox2), all of which are expressed by alveolar
epithelial cells [27, 28]. In a previous study, Nox1 was shown to modulate influenza-induced
inflammation in the early phase (days 3–7) post-infection (p.i.) with a non-lethal dose of influ-
enza [29]. However, the influence of Nox1 after a lethal challenge of influenza infection has not
been reported. It is also unclear how Nox1 might contribute to the development of adaptive
immune responses following influenza virus clearance. In this study, we demonstrate that mice
expressing an inactive form of Nox1 (Nox1/Y mice) [30] have improved survival after IAV
challenge compared with C57BL/6 control mice. We also observed alterations to the adaptive
immune response after IAV challenge, including a decreased percentage of virus-specific CD8+
T cells in the lungs, an increased percentage of virus-specific CD8+ T cells expressing the IL-7
receptor (CD127) in the lungs and draining lymph nodes, and an increased percentage of T
cells in the lung and spleen with cytokine effector function ex vivo in Nox1/Y mice. These dif-
ferences were associated with increased CD40 expression on the dendritic cells (DCs) of the
lung-draining lymph node (dLN) in Nox1/Y mice. Our results suggest that Nox1 may nega-
tively influence the optimal development of the early adaptive immune response to IAV
infection.
Results
Nox1 contributes to PR8-induced morbidity and mortality
In a previous report, using mice lacking Nox1 gene, Selemidis et al. [29] reported that Nox1-/Y
mice had increased weight loss at day 3 p.i. along with increased inflammatory mediator gene
expression. However, they also observed that by day 7 p.i. the Nox1-/Y mice had decreased
inflammatory mediators compared with B6 controls. Furthermore, virus-specific cellular
immunity, weight loss and survival after day 7 have not been previously addressed. Since stud-
ies with mice lacking the entire Nox1 gene eliminates a number of possible protein-protein
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interactions, specifically with p22phox, NOXO1, NOXA1, and Rac1, which can proceed nor-
mally when only the active site is affected, we used mice lacking catalytically active domain of
Nox1 (S1 Fig), and compared morbidities and mortalities of influenza A virus infected Nox1/Y
mice with B6 mice. Nox1/Y mice and B6 control mice were infected with PR8 intranasally at
50 MID50. As shown in Fig 1, Nox1-deficiency provided a marked increase (3.7-fold) in sur-
vival following infection (Fig 1A). As expected, both B6 and Nox1/Y mice showed loss of body
weight due to IAV infection, but Nox1/Y mice demonstrated a delay in weight loss between
day 4 and 8 p.i. (Fig 1B). Similar results were observed when animals were challenged with PR8
virus at 1 LD50 (data not shown). These data suggest that Nox1 contributes to the morbidity
and mortality of PR8 influenza virus infection.
Nox1 deficiency leads to altered T cell phenotypes after PR8 infection
The differences observed in morbidity and mortality (Fig 1A and 1B) between Nox1/Y and B6
mice appeared no earlier than day 5 p.i. This coincides with the time at which PR8-specific
CD8+ T cells migrate to the lungs from the lung draining lymph nodes (dLN) [31]. This
prompted us to analyze the phenotype of the T cells arising during PR8 infection. Mice were
infected with a sub-lethal dose of virus, 20 MID50, to allow them to survive long enough to
develop adaptive immune responses. We isolated dLN from B6 and Nox1/Y mice at day 3, 6, 9
and 15 p.i., as well as lungs and spleens at day 9 and 15 p.i. The time points were chosen to per-
mit observation of the development of the T cell response in the dLN and the peak of the T cell
migration to the lung [31].
We first analyzed the total T cell frequencies in the dLN, lungs and spleens. There was no
difference in the frequency of CD4+ T cells between Nox1/Y and B6 mice in any tissue (data
not shown). On average, the Nox1/Y genotype was associated with a higher percentage of
CD8+ T cells in the dLN at day 9 and 15 after PR8 infection (Fig 2A), although no consistent
Fig 1. Nox1*/Y mice have improved survival and delayed weight loss following intranasal challenge with IAV. B6 and Nox1*/Y mice were challenged
with 50 MID50 IAV. Mortality is plotted in A as percentage of mice surviving over time. A significant difference (p<0.01) was observed between the B6 and
Nox1*/Y mortality curves by both the Log-rank test and the Gehan-Breslow-Wilcoxon Tests. Morbidity is plotted in B as percentage of weight on day of
infection (day 0). Results represent mean values ± standard deviation from the mean (S.D.). Average percent original body weights were compared between
B6 and Nox1*/Y mice at individual days p.i. by a Student’s t test. Data compiled from two independent experiments; n = 15–16 mice per group (*, p < 0.05;
**, p = 0.01).
doi:10.1371/journal.pone.0149864.g001
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difference was observed at day 3 or 6 p.i. (data not shown). There was no difference in the per-
centage of CD8+ T cells in the lungs (Fig 2B). Also, the percentage of CD8+ T cells was mod-
estly but significantly increased in the spleens of Nox1/Y mice by day 15 p.i. (Fig 2C).
However, there was no difference in CD4+ or CD8+ T cell frequency between naïve Nox1/Y
and B6 mice (data not shown). We next investigated the frequencies of IAV-specific CD8+ T
cells using a Db-IAV-NP pentamer. We observed a significant decrease in the percentage (Fig
2D and 2E), but not the absolute number (data not shown), of NP-specific CD8+ T cells in the
lungs of Nox1/Y mice at day 15 p.i. No differences were observed in the NP-specific CD8+ T
cell responses of the dLN or spleen (data not shown). To summarize, an increased percentage
of CD8+ T cells was seen in the dLN of Nox1/Y after PR8 infection, with increased CD8+ T
cells in the spleens of Nox1/Y mice by day 15 p.i. However, this correlated with a decreased fre-
quency of NP-specific CD8+ T cells in the lungs at day 15 p.i.
Having observed a modest difference in the percentage of NP-specific CD8+ T cells in the
lungs between Nox1/Y and B6 mice, we next investigated the phenotypes of these cells based
on surface protein expression. During the expansion of a CD8+ T cell response after antigen
stimulation, the progeny cells acquire genetic programming which directs their fate during the
contraction of the response. In the mouse models of infection with vesicular stomatitis virus or
Fig 2. Lack of Nox1 catalytic activity alters frequencies of CD8+ T cells after IAV infection. Single-cell suspensions of dLN (A), lung (B, D, E) and spleen
(C) harvested from B6 and Nox1*/Y mice at day 9 and 15 p.i. were stained with antibodies and Db-NP-IAV pentamer then analyzed by flow cytometry. CD19+
cells were excluded from singlet lymphocyte events before differential CD4+ and CD8+ gating. NP multimer+ cells were gated from CD8+ cells as
demonstrated in the representative FACS dot plots in E. E gated on the day 15 lung CD8+ T cell populations. Results in A-D plotted as individual mice with
the horizontal bar indicating the mean. 2-way ANOVA indicates that the Nox1*/Y genotype affects the percentage of CD8+ T cells plotted in A (p < 0.05), C
(p < 0.01) and D (p < 0.05). Bonferonni post-test indicates significant difference between B6 and Nox1*/Y mice at day 15 p.i. for C and D. Data compiled from
two independent experiments; n = 9–11 mice per group (*, p < 0.05; **, p < 0.01).
doi:10.1371/journal.pone.0149864.g002
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Listeria monocytogenes, surface expression of the IL-7 receptor (CD127) identifies cells fated to
survive contraction and develop into the memory population [32, 33]. Also, surface expression
of KLRG-1 identifies cells with a decreased propensity to replicate, and that are more likely to
undergo programmed apoptosis during the contraction of the CD8+ T cell response (reviewed
in [33]). No change was noted in the percentage of NP-specific CD8+ T cells expressing KLRG-
1 in the lung (Fig 3A), dLN (Fig 3B), and spleen (data not shown). However, we observed a
Fig 3. Nox1*/Y mice have a greater percentage of CD127+ NP-specific CD8+ T cells at day 15. Single-cell suspensions of lung (A, C, E) and dLN (B, D,
F) harvested from B6 and Nox1*/Y mice at day 9 and day 15 p.i. were stained with antibodies and Db-NP-IAV pentamer then analyzed by flow cytometry.
CD19+ cells were excluded from singlet lymphocyte events before differential CD4+ and CD8+ gating. CD127 and KLRG-1 staining was analyzed on Db-
NP-IAV pentamer+ cells among CD8+ cells as demonstrated in the representative FACS dot plots taken from day 15 p.i. samples in A and B. Results in C-F
plotted as individual mice with horizontal bar indicating mean. 2-way ANOVA indicates that the Nox1*/Y genotype contributes to increased lung CD127+ cells
(C, p < 0.001) and decreased double-negative CD127-KLRG-1- expressing cells (E, p < 0.0001; F, p < 0.05). Bonferonni post-test indicates significant
difference between B6 and Nox1*/Y mice at day 15 p.i. for C and D, and at both day 9 and day 15 for E. Data compiled from two independent experiments;
n = 9–11 mice per group (*, p < 0.05; **, p < 0.01; ****, p < 0.0001).
doi:10.1371/journal.pone.0149864.g003
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significant increase in cells expressing CD127 in both the lung (Fig 3A and 3C) and dLN (Fig
3B and 3D) of Nox1/Y mice at day 15 p.i. Cells expressing neither CD127 nor KLRG-1 were
correspondingly decreased in these tissues (Fig 3A, 3B, 3E and 3F) from Nox1/Y mice. In sum-
mary, the NP-specific CD8+ T cells in Nox1/Y mice express more CD127 than those in B6
mice at day 15 p.i.
Antigen-specific T cells produce cytokines upon activation by cognate antigen encounter
[34–36]. To determine whether Nox1 affected the cytokine production capacity of T cells
responding to IAV challenge, we compared the cytokine production of PR8-specific T cells
from Nox1/Y mice with those from B6 mice by ex vivo intracellular cytokine assay. While no
differences were seen at day 9 p.i. (data not shown), an increase was seen in the percentage of
Nox1/Y lung CD4+ T cells which produced IL-2 after overnight stimulation with PR8 (Fig 4A
and 4E). We also observed increases in both the percentages of splenic CD4+ T cells from
Nox1/Y mice able to produce IFN-γ and those able to produce TNF-α (Fig 4B, 4C, 4F and
4G). Furthermore, a higher percentage of CD8+ T cells in Nox1/Y spleens produced TNF-α
than B6 controls (Fig 4D and 4H). We further analyzed the cytokine effector function of the
CD4+ and CD8+ T cell populations by Boolean gating our multiparameter flow cytometry data
as described by Seder et al. [37]. We observed that a greater percentage of splenic T cells from
IAV-infected Nox1/Y mice were able to produce more than one cytokine in response to anti-
gen at day 15 p.i. Specifically, Nox1/Y mice had a greater percentage of triple cytokine-produc-
ing CD4+ T cells in their spleens than B6 controls (Fig 4I, 4K and 4L). Nox1/Y mice also had a
greater percentage of double cytokine-producing CD8+ T cells in their spleens (Fig 4J, 4M and
4N). Together, these results indicate that by day 15 p.i., Nox1/Y mice have both a greater per-
centage of PR8-specific T cells which have cytokine effector function, and a greater percentage
of PR8-specific T cells which are cytokine multipotent, in response to antigen stimulation.
No effect on B cell responses observed with Nox1 deficiency
The antibody-mediated adaptive immune response to IAV is the most important correlate of
protection from disease [38]. CD4+ T cells provide help to B cells to produce the optimal quan-
tity and quality of antibodies after antigen exposure [39, 40]. Having observed increased cyto-
kine production from CD4+ T cells after ex vivo stimulation in the spleen and lung of Nox1/Y
mice, we investigated the B cell response for corresponding changes. We observed no consis-
tent difference in the frequency or number of PR8-specific IgM or IgG producing B cells as
measured by ELISpot at day 9 or 15 p.i. (data not shown). B cells are thought to encounter IAV
antigen in the dLN as early as day 3 p.i., and class-switched B cells are apparent within the first
week p.i. [41]. Therefore, we queried the surface phenotypes of the B cells in the dLN at day 3
and 6 p.i. As determined by FACS analysis, the frequency of IgD- class-switched B cells (Fig
5A) and germinal center B cells (Fig 5B) was unchanged in the dLN at day 3 to 6 after IAV
infection. We did not observe any difference in hemagglutination inhibition (HAI) titers at day
9 or 15 (Fig 5C). Overall, we observed little impact of Nox1 deficiency on the magnitude of the
B cell-mediated early immune response to IAV.
CD40 expression on DCs is enhanced at early time points in dLN of
Nox1-deficient mice
The differences we observed in the phenotype and function of T cells between Nox1/Y and B6
mice at day 15 after PR8 IAV infection may be linked to differences in the priming environ-
ment of the T cells [32, 33, 42]. Therefore, we investigated the early priming environment of
the T cells in the lung and dLN. The lungs and dLN of mice were isolated at day 3 and 6 p.i.
after the same sublethal dose of virus (20 MID50) at which the differences in T cell phenotypes
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Fig 4. Nox1*/Y mice have increased IAV-specific cytokine-producing T cells at day 15. Single-cell suspensions of lung (A, E) and spleen (B-D, F-N)
harvested from B6 and Nox1*/Y mice at day 15 p.i. were incubated overnight in the presence or absence of IAV at 1 MOI. Next, cells were stained
extracellularly and intracellularly with antibodies and analyzed by flow cytometry. CD4+ and CD8+ populations gated from singlet lymphocyte events. A-D,
representative dot plots of virus-stimulated B6 or Nox1*/Y cells gated on the indicated T cell population. E-H, individual cytokines presented as a percent of
the CD4+ or CD8+ populations. Results represent mean values ± S.D. I-J, representative dot plots of virus-stimulated B6 or Nox1*/Y cells gated on the
indicated T cell population. Red dots are IL-2+. K-N, data from Boolean gating of cytokines gated as in A-D presented as a percent of total cytokine (IFN-γ,
TNF-α or IL-2)-producing CD4+ or CD8+ T cells. 2-way ANOVA indicates that the Nox1*/Y genotype contributes to increased cytokine-producing cells after ex
vivo virus stimulation in E-H (p < 0.01). Bonferroni post-test indicates significant difference between stimulated cells from B6 and Nox1*/Y mice for E-H. Data
compiled from two independent experiments; n = 11 mice per group (**, p < 0.01; ***, p < 0.001).
doi:10.1371/journal.pone.0149864.g004
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were observed at day 15 p.i. Lungs were homogenized and queried for inflammatory markers
and viral titers. As shown in Fig 6, no consistent difference was observed in markers of lung
inflammation between B6 and Nox1/Y mice, including cytokines (IL-1β, IL-6, IL-12(p40),
Fig 6. Lack of Nox1 catalytic activity does not affect lung inflammatory protein levels or viral titers. Supernatant harvested from whole lung
homogenate was tested for cytokine and chemokine protein levels by Bioplex assay (A-G) and ELISA (H). Supernatant MPO protein levels were determined
by ELISA (I). IAV titers were determined by EID50 assay (J). Assay limits of detection depicted by dashed horizontal line. Results in A-I represent mean
values ± S.D. All samples run in duplicate; average of two wells used to generate final data. Result in J plotted as individual mice with horizontal bar indicating
mean. Data compiled from two independent experiments, n = 7–8 mice per group.
doi:10.1371/journal.pone.0149864.g006
Fig 5. Germinal center B cell frequencies and HAI titers unaffected by lack of Nox1 catalytic activity. Single-cell suspensions of dLN (A-B) harvested
from B6 and Nox1*/Y mice at day 3 and 6 p.i. were stained with antibodies and analyzed by flow cytometry. A: B220+ IgD- cells were gated from singlet
leukocyte events. B: GC B cells were identified as the CD38- GL7+ population among IgD- B cells. C: day 9 and 15 serum titers of HA-binding antibody as
determined by HAI assay. Results in A-C plotted as individual mice with horizontal bar indicating mean. Data compiled from two independent experiments; in
A & B, n = 8 mice per group; in D, n = 9–11 mice per group.
doi:10.1371/journal.pone.0149864.g005
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IFN-γ, TNF-α, and IFN-β), chemokines (MCP-1, MIP-1β), and myeloperoxidase protein
(MPO). There was also no difference in lung viral titers (Fig 6J), nor apparent differences in
the microscopic appearance of inflammation or in dissemination of virus in the lung tissue har-
vested at day 3 and 6 p.i between B6 and Nox1/Y mice (S2A and S2B Fig). In the dLN, there
were no consistent differences in T or B cell populations at day 3 or 6 p.i (data not shown). No
consistent differences were observed in the percentage of cells comprising the various dLN DC
subsets, including neither the dLN resident DCs: interstitial DCs (iDCs), plasmacytoid DCs
(pDCs), and conventional DCs (cDCs), nor the DCs which traffic from the lung tissue (tDCs)
[43] (data not shown). We also did not observe a change in the frequency of CD86 expression
among any of these populations (data not shown). However, an increased percentage of cells
expressing CD40 was observed among certain DC subsets in the dLN in Nox1/Y mice. There
was an increased frequency of total cDCs expressing CD40 at day 3 p.i. (Fig 7A and 7G), along
with an overall increase in CD40+ cells among the CD8α+ cDC subset (Fig 7B, 7E and 7H) as
well as the iDCs (Fig 7C, 7F and 7I) at the early time points. CD40 is expressed on activated
DCs [44] and serves as a costimulatory ligand for activation of DCs by T cells [45–47]. These
data suggest that although lack of Nox1 activity does not appear to affect the gross
Fig 7. A greater percentage of cDCs and iDCs in the dLN of Nox1*/Y mice express CD40. Single-cell suspensions of dLN harvested from B6 and Nox1*/
Y mice at day 3 and 6 p.i. were stained with antibodies and analyzed by flow cytometry. Among SSClo singlet lymphocytes, CD11chi B220hi cells were gated
for the pDC population. All other DC populations were gated from the B220- cells using the gating strategy described by Ballesteros-Tato et al. [43], including
tDCs (CD11c+ MHCIIhi) from which were gated both the CD103+ and CD103- tDC populations, cDCs (CD11chi MHCIIint) from which were gated the CD8α+,
CD4+ and double negative cDC populations, and iDCs (CD11cint MHCIIint). CD40 expression was analyzed on individual DC populations as shown in
representative histogram plots (A-F). Results in G-I plotted as individual mice with horizontal bar indicating mean. 2-way ANOVA indicates the Nox1*/Y
genotype affects the percentage of populations graphed in G (p < 0.01), H and I (p < 0.001). Bonferonni post-test indicates significant difference between B6
and Nox1*/Y mice at day 3 p.i. for G. Data compiled from two independent experiments; n = 9–11 mice per group (*, p < 0.05).
doi:10.1371/journal.pone.0149864.g007
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inflammation level in the lungs of PR8-infected mice after sublethal infection, it may alter cost-
imulatory signals involved in T cell priming.
Discussion
Reactive oxygen has long been proposed to play a role in inflammation including that of the
lung. Several studies showed that Nox2 contributes to immunopathology following IAV infec-
tion [23, 25, 26]. The role of other Nox-family enzymes expressed in the lung [27] have been
less thoroughly investigated. In our studies, Nox1/Y mice had a significant improvement in
survival and morbidity assessed by weight loss after IAV challenge. At a sublethal dose of virus,
Nox1/Y mice also had altered T cell phenotypes by day 15 p.i. However, it is not clear that the
phenotypic changes to the T cell population observed at day 15 p.i after a sublethal challenge
are related to differences in morbidity and mortality observed as early as day 5 p.i. after a lethal
challenge. At early time points, we failed to observe differences between wild-type and Nox1/Y
mice by measurements of inflammation, nor did we observe a difference in lung viral titers.
This suggests the effects of Nox1-generated ROS on survival may be more subtle, perhaps
involving signaling pathways in the lung or in other organs. Consistent with this interpretation,
at days 3 and 6 p.i. certain DC subsets within the draining lymph nodes had increased CD40
expression. Together, these results suggest that Nox1 plays a role in increasing mortality after
IAV infection, perhaps related to or in parallel with the role of Nox1 in signaling events during
priming of the early adaptive immune response.
To our knowledge, there is only one other published study investigating the role of Nox1 in
IAV infection: using mice lacking the entire Nox1 gene, Selemidis, et al. [29] reported increased
weight loss and increased inflammation in Nox1-/Y mice as determined by histology, indicators
of oxidative stress, and gene expression of inflammatory mediators. Furthermore, alterations to
neutrophils and macrophages, but no changes to adaptive immune cell populations, recovered
by bronchoalveolar lavage were reported. Importantly, there were several differences between
our model system and that used by Selemidis, et al. The Selemidis, et al. study used Nox1-/y
mice which lack any Nox1 protein expression [48]. In contrast the Nox1-deficient mice used
herein express a catalytically deficient Nox1 protein that is expressed under the control of its
normal promoter [30]. This may result in some differences in phenotype. For example, the
truncated protein may be capable of interacting with some of its normal protein binding part-
ners such as p22phox, which shares interactions with other Nox isoforms (Nox2, Nox3, Nox4)
[49, 50]. Also, Selemidis, et al. used HkX-31 IAV infection, an H3N2 laboratory strain of IAV,
while we used PR8, an H1N1 laboratory strain of IAV that is known to be more virulent than
HkX-31 in mice [51]. Finally, Selemidis, et al. investigated the cellular immune response to
IAV in the BALF through day 7 p.i. Most of the differences we report herein are in spleen,
draining lymph node, or whole lung, with important differences in T cell phenotypes not
appearing until 15 days p.i. The different experimental approaches used might also be expected
to generate differing results, including querying changes in the cytokine and chemokine
responses by mRNA levels rather than protein levels, and sampling immune cell subsets from
the BALF in contrast to whole, unperfused lung. Taken together, the differences in model sys-
tems and experimental approaches make comparisons difficult and may account for apparent
contrasts between the two studies.
The mechanism for the increased survival of Nox1/Y mice compared with B6 controls in
our study remains unknown. Excessive lung inflammation can exacerbate pathology [11] but
convincing differences in measures of lung inflammation (inflammatory proteins, lung wet
weights (data not shown) and histology), were not observed, consistent with the lack of differ-
ence in morbidity and mortality between the Nox1/Y and B6 mice before day 5 p.i. B-cell
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mediated IAV-specific antibody responses are the most important correlate of protection from
IAV [38], and we were unable to observe any difference in B cell responses or antibody titers,
which may explain the modest difference in morbidity and mortality observed. Virus is typi-
cally cleared from the mouse lung by day 6–8 p.i. [52–54], and we observed no difference in
viral titers during this timeframe. Furthermore, when compared with B6 controls, Nox1/Y
mice had equivalent percentages of NP-specific CD8+ T cells in their lungs at day 3, 6 (data not
shown) and 9 p.i. This suggests that the alterations to T cell phenotypes arising by day 15 p.i.
are likely to be consequences of earlier differences in T cell programming during the expansion
phase, rather than contributing to improved survival of Nox1/Y mice through antiviral activ-
ity. Therefore, it is possible that other signaling pathways and resulting effector molecules
induced by influenza virus infection of Nox1/Y mice may be responsible for increased survival.
Further studies addressing the role of Nox1 in different cell types, both in the lymphoid organs
and peripheral tissues, may help to explain the improved survival of Nox1/Y mice.
The surface phenotype of CD8+ T cells can be affected by the priming environment as well
as the differentiation stage of the clone [32, 42]. For example, in the vesicular stomatitis virus
and Listeria monocytogenesmodels, the ratio of CD127+ memory precursor effector cells to
KLRG-1+ short lived effector cells is linked to the level of inflammation during priming, with
lower inflammation favoring a larger proportion of memory precursor effector cells and higher
inflammation skewing the response towards short lived effector cells [55]. In this study, a
greater percentage of the NP-specific CD8+ T cells in the lung and dLN of Nox1/Y mice
expressed CD127, which corresponded with a decrease in the frequency of CD127-KLRG-1- T
cells without a change in the KLRG-1-expressing cells. In the VSV and L.m. models, the double
negative CD127-KLRG-1- population is a precursor to both the CD127- and KLRG-1-express-
ing populations [32]. Therefore, increased CD127 expression on the Db-IAV-NP-specific
CD8+ T cells may indicate that the NP-specific CD8+ T cells in Nox1/Y mice have advanced
further in the process of differentiation by day 15 p.i. than their B6 counterparts. When the fact
that there are fewer NP-specific CD8+ T cells in the lungs of Nox1/Y mice at this same time
point is taken into account, we can speculate that this population is undergoing contraction
earlier than the corresponding B6 population. However, the contraction of the CD8+ T cell
response is mediated by cytokine signals [56]. No differences were seen between B6 and
Nox1/Y mice in lung cytokine expression at day 3 or 6 p.i., but the levels of cytokines in the
lungs or dLN at later time points p.i. were not measured.
Production of cytokines is one of the effector functions of an activated T cell [34, 57]. Pro-
duction of IFNγ, TNFα and IL-2 have been shown to be hierarchical in the IAV-specific
response, with IFN-γ being produced by most IAV-specific CD8+ T cells, of which a subset can
produce TNF-α, and only the most functionally differentiated cells produce IL-2 [37, 58].
CD4+ T cells can also produce all three cytokines after IAV infection [36], and among influ-
enza-specific CD4+ T cells in human blood, triple cytokine producers are functionally superior
to single-producers [59]. A larger percentage of CD4+ T cells in the Nox1/Y spleens produced
all three cytokines, while a larger percentage of CD8+ T cells in Nox1/Y spleens produced two
of these cytokines. CD4+ T cells, with their known T-helper function, are expected to produce
higher levels of cytokines than the CD8+ T cells [60]. When viewed alongside the increased
CD127 expression of NP-specific CD8+ T cells in the lung and dLN, the increased percentage
of cytokine-producing IAV-specific T cells in the lung and spleens suggests that by day 15 p.i.
Nox1/Y mice have a T cell response that would be better able to respond to IAV re-challenge.
Changes in the phenotype and cytokine-producing functions of T cells in IAV-infected
mice compared to B6 controls raises the question of the relationship between Nox1-expressing
cell types and mechanisms that influence T cell priming. Earlier studies in murine model [29]
and in human lung [61] have shown Nox1 expression in alveolar epithelial cells, bronchial
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cells, and endothelium. Results from our preliminary studies showed an increase in
Nox1mRNA expression in IAV-infected human epithelial (A549), endothelial (HULEC) and
monocytic (THP-1) cell lines (data not shown). Furthermore, when compared with lung tissue
from naïve mice, IAV (A/PR8 and A/Mexico/4108/2009)-infected Nox1/Y mice show increase
in Nox1mRNA expression at 24h and 48h p.i. (data not shown). Therefore it is possible that
virus replication in the respiratory epithelium and the ensuing cytokine/chemokine milieu may
induce an increase in Nox1 expression in lung resident cells and lung infiltrating antigen pre-
senting cells that may alter virus dissemination, antigen presentation and T cell priming.
Future studies are planned to address this possibility.
In the context of influenza infection, the co-stimulatory molecule CD40 has a role in helping
both the CD4+ and CD8+ T cell responses. CD40 has been shown to help the influenza-specific
CD8+ T cells survive premature contraction mediated by Tregs [62]. It is interesting to note
that although we see increased CD40 on Nox1/Y dLN DCs, and increased CD127 expression
and decreased CD127-KLRG-1- NP-specific CD8+ T cells in the lungs and dLN of Nox1/Y
mice at day 15 p.i., we also saw a decreased frequency of NP-specific CD8+ T cells in the lungs.
This emphasizes the importance of determining the role of Nox1 in the contraction of the
IAV-specific CD8+ T cell response. CD40 is also involved in the self-help feedback loop of
influenza-specific CD4+ T cells, in which previously primed CD4+ T cells license DCs to better
prime the next generation of CD4+ T cells [63]. The increased percentage of IFNγ and TNFα
produced by CD4+ T cells from the spleen after ex vivo virus re-stimulation indicate a greater
percentage of IAV-specific CD4+ T cells are present [63]. This suggests that some aspect of this
CD4+ T cell feedback loop operates more efficiently in Nox1/Y mice than in B6 mice.
ROS are generated in a controlled manner via the activity of Nox enzymes in most or all tis-
sues, and play roles in both normal physiology and disease [50, 64]. We demonstrate here that
normal expression of native, catalytically intact Nox1 enzyme results in increased mortality
after IAV infection, accompanied by earlier and more severe weight loss compared to mice
expressing catalytically-inactive Nox1. Nox1/Y mice appeared to have improved T cell
responses over normal mice including increased CD127 expression and ex vivo cytokine pro-
duction by day 15 p.i. This was associated with increased CD40 expression on DC subsets in
the dLN at day 3 and 6 after infection. Our results suggest that Nox1 activity contributes to
mortality at the peak of influenza virus infection, while having an inhibitory effect on develop-
ment of the early adaptive immune response. Although some ROS inhibitors have shown
immunomodulatory effects [19], based on our findings, the use of Nox1-selective inhibitors
should be explored as an adjunct therapy (e.g., along with antivirals) to decrease the mortality
and morbidity associated with influenza.
Materials and Methods
Mice and virus infections
Mice expressing catalytically inactive Nox1 were generated by crossing Nox1loxp/loxp mice
(described in [30]) with mice expressing the germline specific Zp3-cre. Because Nox1 is
encoded on the X chromosome, the offspring of these crosses were bred to generate Cre-
expressing, and therefore Nox-truncated, hemizygous males (designated as Nox1
/y). Second
mating was required between the males derived from the Cre/floxed Nox1 and females of
same cross to generate females that were homozygous Nox1-inactive mice, which were con-
tinuously mated with the Nox1-inactive male mice. Schematic representation of exon 13, lac
Z insertion site, primer sets used for genotyping of mice and beta-galactosidase expression is
shown in S1A–S1C Fig. The colony of Nox1-modified mice was maintained at Charles River
(Wilmington, MA). Four to six week old male Nox1/Y and control C57Bl/6 (B6) mice were
Role of Nox1 Oxidase after Influenza A Virus Infection
PLOS ONE | DOI:10.1371/journal.pone.0149864 February 24, 2016 12 / 19
housed in a specific pathogen-free environment in an Association for Assessment and
Accreditation of Laboratory Animal Care International-accredited facility at the Centers for
Disease Control and Prevention under the guidance of the Centers for Disease Control and
Prevention’s Institutional Animal Care and Use Committee (IACUC, animal welfare assur-
ance number A4365-01). The studies performed were approved by the IACUC (approved
Protocol Number: 2406).
A/Puerto Rico/8/34 (PR8) virus was grown and stored as described [65]. PR8 was titrated
for 50% lethal and 50% mouse infectious doses (LD50 and MID50, respectively) by administer-
ing serial ten-fold dilutions of egg-grown virus stock to 6-week old female B6 mice. Lethality,
as defined by loss of greater than 25% original body weight, or infection, defined by positive
Egg Infectious Dose (EID) titers in the lungs at day 3 p.i., were used as endpoints to determine
LD50 or MID50 titers respectively, in the method described by Reed and Muench [66]. Age-
matched mice were infected intranasally at 5–8 weeks of age with 50 MID50 or 20 MID50 of
PR8 under anesthesia (Avertin; Sigma-Aldrich). Since the virus stock dilutions required for
preparing a virus dose/inoculum (50μl) of 50 MID50 and LD50 varied by less than 2-fold dilu-
tion, clinical symptoms and lethality was evident at the calculated dose of 50 MID50. As per
approved IACUC protocol, animal suffering and distress was minimized by following AALAS
approved trainings for handling and care of animals. IACUC approved anesthetic was used
during virus infection of mice. However, analgesics and anesthetics were not used during the
observation period since both analgesics and anesthetics can interfere with outcomes such as
inflammation and immune response to influenza infection [67]. The animals were monitored
twice daily and there were no unexpected deaths during the observation period. In the survival
studies, mice which lost more than 25% original body weight were humanely euthanized using
IACUC protocol approved method, i.e., cervical dislocation under Avertin anesthesia. Mice
which never dropped below 100% of original body weight were presumed to be uninfected and
were omitted from longitudinal studies.
Genotyping of Nox1*/Y mice
Tail genomic DNA was prepared using Wizard1 Genomic DNA Purification Kit (A1120,
Promega). PCR was performed using following primer sets; FP-GTACTGCTCTACTCTTACA
GG; RP1- GCAAGTGTCAGCCAGCAA; RP2-CTTCGCTATTACGCCAGCTG. Amplifica-
tion was done using Redextract-N-Amp (R4775, Sigma) with the following PCR program;
95°C, 3 min, 1 cycle; 95°C, 30 sec; 52°C 20 sec; 72°C, 20 sec for 35 cycles; 72°C, 3 min followed
by hold at 4°C. PCR products were analyzed by running 5μl on an ethidium bromide agarose
gel (1.5%) and visualized by UV light. As a marker of gene expression, tongue harvested from
wild type and Nox1/Y mice were screened for beta-galactosidase activity using standard proto-
col. Briefly, specimen was fixed in 10mM periodate-lysine-4% paraformaldehyde followed by
3x wash with PBS and incubation in a solution containing 20 mM dithiothreitol, 150 mM Tris
Base, and 20% ethanol for 45 min at RT. After 3x wash with PBS, specimen was incubated in
solution containing 2 mM X-gal, 4 mM potassium ferricyanide, 4mM potassium ferrocyanide,
2 mMMgCl2 in PBS, overnight at 4°C.
FACS Analysis
Tissues were collected and processed to single-cell suspensions as follows: lungs were
homogenized by incubation with collagenase I (263 U/ml) and lymphocytes were isolated by
density gradient centrifugation (Lymphoprep; Stemcell Technologies); dLN and spleens
were gently dissociated and incubated in collagenase IV (297 U/ml) for 30 min before filter-
ing through a 40μM cell strainer followed by incubation in Red Blood Cell Lysis Buffer
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(Sigma-Aldrich) for 3–5 min. For surface stains, 1x106 cells were first blocked with anti-
mouse FcBlock (BD Pharmingen) and then stained with the following antibodies: anti-
KLRG-1, anti-CD44, anti-CD103, anti-CD11c, anti-CD80, anti-CD138, anti-CD3, (Biole-
gend), anti-CD4, anti-CD127, anti-CD8α, anti-CD86, anti-B220, anti-MHC Class II, anti-
CD11b, anti-CD69, anti-CD38, anti-IgD (eBioscience), anti-CD19, anti-CD40, anti-Ly6C,
anti-GL7, and anti-CD86 (BD Pharmingen), as well as with R-PE labelled H-2Db ASNEN-
METM (Db-NP-IAV) pentamer to label IAV nucleoprotein (NP)-specific T cell receptors
(ProImmune). For intracellular cytokine staining, cells were incubated at 37°C with or with-
out 1 multiplicity of infection (MOI) PR8 for 5 hours before overnight addition of GolgiStop
and GolgiPlug at 1:1000 (BD Biosciences). Cells were washed twice with PBS before staining
with anti-CD44, anti-CD8α and anti-CD4, permeabilized with BD Cytofix/Cytoperm, then
stained with anti-IFN-γ, anti-TNF-α (Biolegend), and anti-IL-2 (ebioscience). Events were
collected on a BD LSRII flow cytometer.
ELISpot Assay
MAIPS4510 ELISpot plates (Millipore) were coated with either 100 HA units of PR8, or
0.5 μg of goat anti-mouse unlabeled human adsorbed anti-IgM or -IgG (Southern Biotech)
overnight at 4°C. Plates were blocked with media supplemented with FBS and washed with 1X
PBS-TWEEN20 (HyClone). 1.5–3 x 106 splenocytes (prepared as for FACS analysis, above)
were added to the plate followed by serial 3-fold dilutions. Plates were incubated overnight at
37°C. Biotinylated anti-mouse IgG or IgM (Southern Biotech) was added at 1:1000 dilution fol-
lowed by alkaline phosphatase-streptavidin (Southern Biotech) at 1:1000 dilution. ELISpot
plates were developed with Vector Blue Substrate Kit (Vector Laboratories). Spots were
counted using an ImmunoSpot Analyzer (CTL).
Virus titers
Lungs were harvested and frozen on dry ice before storage at -80°C. Lung viral titers were
determined by EID assay as previously described [65] and calculated using the Reed-Muench
method as described in detail by Balish, et al. [68].
Bioplex Assay and ELISA
Lung supernatants (see Methods for ‘Virus titers’, above) were added in duplicate to a Bioplex
plate (Bio-Rad) previously coated with anti-mouse antibody-conjugated beads specific for IL-
1β, IL-6, IL-12 (p40), IFN-γ, MCP-1, MIP-1β, and TNF-α. Bioplex plate was processed and
read according to manufacturer’s protocol on a Bioplex 200 Array Reader. Clarified superna-
tants were also added in duplicate to a pre-coated anti-mouse IFN-β ELISA plate (PBL Assay
Science) and at a final dilution of 200-fold to an anti-mouse MPO ELISA plate (Hycult Bio-
tech). ELISA plates were processed according to manufacturer’s directions and read at an
absorbance of 450 nm on a BioTek Synergy 4 plate reader.
Histology & Immunohistochemistry
Whole lungs were excised from mice and placed into 10% neutral buffered formalin. After 48
h, formalin was decanted and replaced with 70% ethanol. Fixed tissues were embedded in par-
affin and 4 micron sections were taken for routine hematoxylin and eosin (H&E) stain and
immunohistochemical (IHC) assay. IHC assay was performed by using a polymer-based color-
imetric indirect immunoalkaline phosphatase method with a monoclonal antibody against the
nucleoprotein of influenza A virus.
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HAI titer
Serum samples were treated with 3 volumes of receptor destroying enzyme (RDE) (Denka Sei-
ken) at 37°C for 18 hours followed by inactivation of the RDE via incubation at 56°C for 30
min. Serum at a final dilution of 1:10 in PBS was added in duplicate to 96-well V-bottom plates,
and further two-fold serial dilutions were generated. Four hemagglutination units of PR8 were
added to each well and incubated for 30 min at RT. One-percent turkey RBCs (Lampire Biolog-
ical Laboratories) in 50μL were added to each well and the plates were incubated for 30 min.
HAI titers were determined as the highest dilution where RBCs movement was unrestricted by
agglutination.
Statistics
For differences in weight loss, the average percentage of original body weight of the B6 and
Nox1/Y mice was compared by a Students t test for individual days p.i. Survival curves were
compared using both the Log-Rank test and the Gehan-Breslow-Wilcoxon tests. HAI titers
were compared for each of day 9 and day 15 data by MannWhitney t test. Immune cell number
or frequency, viral titers, and Bioplex data were compared by 2-way ANOVA with the Bonfer-
onni multiple comparisons post-test, including data from both day 3 and day 6, or from both
day 9 and day 15. Day 15 intracellular cytokine data were compared by 2-way ANOVA with
the Bonferonni multiple comparison post-test. All error bars indicate standard deviations from
the mean. All statistics were obtained using Prism (GraphPad).
After analysis of the data by 2-way ANOVA, we had situations where the ANOVA deter-
mined that there was a significant difference due to genotype between the two groups. This
analysis takes all the data points into account, irrespective of day post-infection. These results
are reported in the figure legend but not on the figures themselves. To further determine
whether the significance between the two groups was in part due to a significant difference
between the two genotypes at one particular day post-infection, we conducted post-tests. In
some cases, the post-tests determined that there was a significant difference at one of the days
post-infection. This was indicated on the figure with a star. In other cases, the post-tests could
not determine a difference between the two genotypes at a specific day individually. This does
not negate the significant difference between the two groups when all the data is taken into
account. However, in these cases, we only described the difference by ANOVA in the figure leg-
end without denoting it by any star symbol in the graphs.
Supporting Information
S1 Fig. Characterization of mice lacking catalytic domain of Nox1. A Schematic representa-
tion of exon 13 in wild type and Nox1/Y with FP, RP1, and RP2 showing forward and reverse
primers used for genomic DNA PCR-based genotyping. B, PCR results from wild type and
Nox1/Y showing 400bp and 200 bp PCR products respectively. C, beta-galactosidase staining
in wild type and Nox1/Y are shown.
(TIF)
S2 Fig. Lack of Nox1 catalytic activity does not affect the microscopic appearance of inflam-
mation or dissemination of virus at day 3 or 6 p.i. A, Representative H&E staining on histo-
logical sections from mouse lungs taken at the indicated day p.i. Magnification, 100x. B,
Representative NP-specific immunostaining (pink) on hematoxylin-stained histological sec-
tions from mouse lungs taken at the indicated d p.i. Magnification, 200x.
(TIF)
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